Effect of 3,4-diaminopyridine at the murine neuromuscular junction

被引:6
|
作者
Ng, Fiona [1 ]
Lee, Diana C. [1 ]
Schrumpf, Leah A. [1 ]
Mazurek, Mary E. [1 ]
Lee, Victoria [1 ]
Gill, Sharleen K. [1 ]
Maselli, Ricardo A. [1 ]
机构
[1] Univ Calif Davis, Sch Med, Dept Neurol, Davis, CA 95616 USA
关键词
3,4-diaminopyridine; Lambert-Eaton myasthenic syndrome; congenital myasthenic syndromes; neuromuscular junction; quantal release; endplate potential; CONGENITAL MYASTHENIC SYNDROME; MUTATIONS; TRANSMISSION; MUSK; 4-AMINOPYRIDINE; PHENOTYPES; ANTIBODY; RELEASE; AGRIN; FROG;
D O I
10.1002/mus.25208
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: We investigated the effects of 3,4-diaminopyridine (3,4-DAP) and its acetylated metabolite, N-(4-amino-pyridin-3-yl) acetamide (3-Ac), at the mammalian neuromuscular junction. Methods: Quantal release of acetylcholine was studied in diaphragm muscles of mice, using in vitro intracellular microelectrode recordings. Results: Under conditions of low probability of release, 3,4-DAP produced a 1,000% increase in quantal release, but 3-Ac had no effect. Under conditions of normal probability of release, the effect of 3,4-DAP was modest and limited by concurrent depletion of synaptic vesicles, especially with high concentrations of 3,4-DAP and high frequencies of nerve stimulation. Conclusions: These findings predict 3,4-DAP is most effective in conditions with low probability of quantal release, such as Lambert-Eaton myasthenic syndrome. A beneficial effect is also expected in disorders of neuromuscular transmission in which the effect of 3,4-DAP on quantal release is not limited by depletion of synaptic vesicles, such as postsynaptic congenital myasthenic syndromes. Muscle Nerve, 2016 Muscle Nerve55: 223-231, 2017
引用
收藏
页码:223 / 231
页数:9
相关论文
共 50 条
  • [1] EFFECT OF 3,4-DIAMINOPYRIDINE AND ITS ACETYLATED METABOLITE AT THE MURINE NEUROMUSCULAR JUNCTION
    Maselli, R. A.
    Ng, F.
    Lee, D. C.
    MUSCLE & NERVE, 2015, 52 : S140 - S140
  • [2] Therapeutic efficacy of 3,4-Diaminopyridine phosphate on neuromuscular junction in Pompe disease
    Cinzia, Bragato
    Flavia, Blasevich
    Gary, Ingenito
    Renato, Mantegazza
    Lorenzo, Maggi
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 137
  • [3] THE EFFECTS OF 3,4-DIAMINOPYRIDINE ON ACETYLCHOLINE-RELEASE AT THE FROG NEUROMUSCULAR-JUNCTION
    DURANT, NN
    MARSHALL, IG
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1980, 67 (2-3) : 201 - 208
  • [4] 3,4-diaminopyridine
    Rubin-Preminger, Janice M.
    Englert, Ulli
    ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2007, 63 : O757 - O758
  • [5] EFFECTS OF 4-AMINOPYRIDINE AND 3,4-DIAMINOPYRIDINE ON TRANSMITTER RELEASE AT THE NEUROMUSCULAR-JUNCTION
    THOMSEN, RH
    WILSON, DF
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1983, 227 (01): : 260 - 265
  • [6] ANTAGONISM OF THE NEUROMUSCULAR BLOCKING EFFECT OF POLYMYXIN-B BY 3,4-DIAMINOPYRIDINE
    FANG, XM
    ZHANG, YP
    SHI, YL
    WANG, WP
    ACTA PHARMACOLOGICA SINICA, 1987, 8 (01): : 22 - 25
  • [7] EFFECTS OF 3,4-DIAMINOPYRIDINE ON SPONTANEOUS AND EVOKED TRANSMITTER RELEASE AT FROG NEUROMUSCULAR-JUNCTION
    DURANT, NN
    MARSHALL, IG
    JOURNAL OF PHYSIOLOGY-LONDON, 1978, 280 (JUL): : P21 - P21
  • [8] PHARMACOLOGY OF 3,4-DIAMINOPYRIDINE
    VOHRA, MM
    PRADHAN, SN
    ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, 1964, 150 (3-4): : 413 - &
  • [9] 3,4-Diaminopyridine may improve neuromuscular block during botulism
    Arnaud Friggeri
    Frédéric Marçon
    Sandra Marciniak
    Anne-Sophie Lemaire-Hurtel
    Abdoul Aziz Seydi
    Nacim Ammenouche
    Mélanie Levrard
    Yazine Mahjoub
    Norik Airapetian
    François Tinturier
    Michel Petitjean
    Hervé Dupont
    Critical Care, 17
  • [10] 3,4-Diaminopyridine may improve neuromuscular block during botulism
    Friggeri, Arnaud
    Maron, Frederic
    Marciniak, Sandra
    Lemaire-Hurtel, Anne-Sophie
    Seydi, Abdoul Aziz
    Ammenouche, Nacim
    Levrard, Melanie
    Mahjoub, Yazine
    Airapetian, Norik
    Tinturier, Francois
    Petitjean, Michel
    Dupont, Herve
    CRITICAL CARE, 2013, 17 (05):